Trials / Completed
CompletedNCT02428478
Effect of Desipramine on Genioglossus Muscle Activity in Healthy Adults Study A
The Effect of Desipramine on Genioglossus Muscle Activity During Sleep in Healthy Control Subjects
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 17 (actual)
- Sponsor
- Brigham and Women's Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 60 Years
- Healthy volunteers
- Accepted
Summary
Obstructive sleep apnea (OSA) is common and has major health implications but treatment options are limited. OSA patients show a marked reduction in upper airway (UA) dilator muscle activity at sleep onset and this phenomenon leads to increased collapsibility of UA compared to normal participants. Until recently, the search for medicines to activate pharyngeal muscles in sleeping humans has been discouraging. However, exciting new animal research has shown that drugs with noradrenergic and antimuscarinic effects can restore pharyngeal muscle activity to waking levels. In this protocol the investigators will test the effect of desipramine (a tricyclic antidepressant with strong noradrenergic and antimuscarinic effects) on genioglossus muscle activity (EMG GG) during sleep in healthy control participants.
Detailed description
Two overnight sleep studies, a placebo night and a drug night, will be performed approximately one week apart in random order. The placebo or drug will be administered 2 hours before lights out. At least 15 minutes of quiet wakefulness will be recorded to quantify the participant's awake EMG GG activity. Participants will then sleep in the lateral position to minimize pharyngeal resistance similar to previous studies of this kind. The same will be done for stable non-rapid eye movement (NREM) and rapid eye movement (REM) sleep (free of arousals and other artifacts). Both NREM and REM sleep will be analyzed, recognizing that REM is less frequent on these drugs. During the second part of the night, the participants will be connected to a modified continuous positive airway pressure (CPAP) machine (Pcrit3000, Respironics) which can provide a wide range of pressures between 20 and -20 cm H2O in order to modify upper airway pressure and measure change in EMG GG as a function of epiglottic pressure (muscle responsiveness).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Desipramine | 200 mg administered 2 hours before normal sleep time |
| DRUG | Placebo | Placebo-matching desipramine administered 2 hours before normal sleep time |
Timeline
- Start date
- 2015-03-01
- Primary completion
- 2015-11-01
- Completion
- 2016-03-01
- First posted
- 2015-04-28
- Last updated
- 2017-03-30
- Results posted
- 2017-03-30
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02428478. Inclusion in this directory is not an endorsement.